Similar articles

• Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

  Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Lavalle-González FJ, et al. Diabetologia. 2013 Dec;56(12):2582-92. doi: 10.1007/s00125-013-3039-1. Epub 2013 Sep 13. Diabetologia. 2013. PMID: 24026211 Free PMC article. Clinical Trial.
• [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].

  Seufert J. Seufert J. Dtsch Med Wochenschr. 2014 Feb;139 Suppl 2:S65-9. doi: 10.1055/s-0033-1359993. Epub 2014 Jan 30. Dtsch Med Wochenschr. 2014. PMID: 24481635 Review. German. No abstract available.
• Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.

  Bailey RA, Damaraju CV, Martin SC, Meininger GE, Rupnow MF, Blonde L. Bailey RA, et al. Am J Manag Care. 2014 Jan;20(1 Suppl):s16-24. Am J Manag Care. 2014. PMID: 24512193 Clinical Trial.
• Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

  Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Forst T, et al. Diabetes Obes Metab. 2014 May;16(5):467-77. doi: 10.1111/dom.12273. Epub 2014 Mar 12. Diabetes Obes Metab. 2014. PMID: 24528605 Free PMC article. Clinical Trial.
• [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

  Menge BA, Meier JJ, Schmidt WE. Menge BA, et al. Med Klin (Munich). 2010 Mar;105(3):163-75. doi: 10.1007/s00063-010-1026-6. Med Klin (Munich). 2010. PMID: 20349294 Review. German. No abstract available.